Publications
Detailed Information
Ifosfamide, methotrexate, etoposide, and prednisolone plus L=asparaginase as a first-time therapy in stage III/IV NK/T-cell lumphoma, nasal typr : III/IV기 NK/T 세포 림프종에서 ifosfamide, methotrexate, etoposide, prednisone 및 L-asparaginase 복합항암화학요법의 치료성적
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Advisor
- 허대석
- Major
- 의과대학 임상의과학과
- Issue Date
- 2014-02
- Publisher
- 서울대학교 대학원
- Keywords
- ifosfamide ; methotrexate ; etoposide ; prednisolone ; L-asparaginase ; NK/T세포 림프종
- Description
- 학위논문 (석사)-- 서울대학교 대학원 : 임상의과학과, 2014. 2. 허대석.
- Abstract
- Introduction: The prognosis of patients with stage III/IV NK/T-cell lymphoma (NTCL) is extremely poor. Although L-asparaginase (L-asp) is effective for NTCL, its significance has not been clearly demonstrated. In addition, there are few studies comparing treatment outcomes in stage III/IV NTCL. This study evaluated the efficacy of L-asp-based chemotherapy and prognostic factors in stage III/IV NTCL.
Patients and Methods: Seventy patients with newly diagnosed stage III/IV NTCL were enrolled between January 2000 and February 2013. Patients received ifosfamide, etoposide, methotrexate, and prednisolone (IMEP) plus L-asp (N=22) or combination chemotherapy without L-asp (N=48) as a first-line treatment. Clinical prognostic factors, treatment outcomes, and prognostic scores were compared between the groups.
Results: After a median follow-up period of 12.8 months (range, 1.1-186.6 months), median overall survival (OS) and progression-free survival (PFS) were 11.3 months and 5.6 months, respectively. Treatment outcomes were superior in patients treated with IMEP plus L-asp compared to those treated with chemotherapy without L-asp (overall response rate 90.0% vs. 34.8%, P < 0.001
complete remission rate 65.0% vs. 21.7%, P = 0.001). The OS and PFS were significantly higher for the IMEP plus L-asp group compared with the chemotherapy without L-asp group. In a multivariate analysis, use of chemotherapy without L-asp was an independent predictor for reduced OS (hazards ratio (HR) = 2.18, 95% confidence interval (CI) 1.08-4.40
P = 0.030) and PFS (HR = 2.29, 95% CI 1.22-4.29
P = 0.010).
Conclusions: IMEP plus L-asp is active against stage III/IV NTCL, and it is an independent predictor for improved survival.
- Language
- English
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.